all report title image
  • Published On : Jul 2022
  • Code : CMI1096
  • Industry : Pharmaceutical
  • Pages : 165
  • Formats :
Ingographics Image

Osteoporosis is a bone related disease that weakens bones and increases the risk of fracture and breaking of bones. The factors responsible for osteoporosis include, long-term use of high-dose oral corticosteroids, a family history of osteoporosis – particularly history of a hip fracture in a parent, having a low body mass index (BMI), heavy drinking and smoking, and others.  Osteoporosis treatment involves preventing and treating fractures and using medication to strengthen bones. The treatment usually includes medications such as Bisphosphonates that are the most common drugs prescribed for osteoporosis. Furthermore, hormone therapy treatment is recommended for post-menopausal women, as they experience a drop in the levels of estrogen, which weakens the bones.

Market Dynamics

Increasing approvals and launches of novel osteoporosis drugs is expected to significantly drive the osteoporosis treatment market growth over the forecast period. For instance, in October 2019, the U.S. Food and Drug Administration had announced the approval of the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with teriparatide injection as the reference drug to Pfenex, a biotechnology company. Like teriparatide injection, the FDA-approved PF708 product is indicated for the treatment of osteoporosis in certain patients at high risk for fracture.

Moreover, in August 2020, Cadila Pharmaceuticals, a multinational pharmaceutical company, had announced the launch of NuPTH an osteoporosis biosimilar of Forteo in India. The Forteo biosimilar is used for treatment of osteoporosis and in patients with increased risk of fracture. The biosimilar NuPTH aims to be a cost effective solution for patients with osteoporosis and will be sold as an easy to use, pre-filled disposable pen.

Key features of the study:

  • This report provides in-depth analysis of the global osteoporosis treatment market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global osteoporosis treatment market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy’s Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., and Pfizer Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global osteoporosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoporosis treatment market

Detailed Segmentation:

  • Global Osteoporosis Treatment Market, By Drug Type:
    • Bisphosphonates
      • Risedronate
      • Ibandronate
      • Zoledronic Acid
      • Others
    • Calcitonin 
    • Hormone Therapy 
    • Selective Estrogen Receptor Modulators (SERMs) 
    • Parathyroid Hormone-Related Protein (PTHrP) Analog 
    • Rank Ligand (RANKL) Inhibitor 
  • Global Osteoporosis Treatment Market, By Route of Administration:
    • Oral
    • Injectable
    • Others
  • Global Osteoporosis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Osteoporosis Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Teva Pharmaceutical Industries Ltd.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Teva Pharmaceutical Industries Ltd.
    • DAIICHI SANKYO COMPANY, LIMITED
    • Amgen Inc.
    • Reddy’s Laboratories Ltd.
    • Viatris Inc.
    • Ligand Pharmaceuticals Incorporated
    • Eli Lilly and Company
    • Asahi Kasei Corporation
    • Hoffmann-La Roche Ltd
    • EffRx Pharmaceuticals SA
    • Novartis AG
    • Merck & Co., Inc.
    • GSK plc.
    • Pfizer Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Detailed Segmentation:

  • Global Osteoporosis Treatment Market, By Drug Type:
    • Bisphosphonates
      • Risedronate
      • Ibandronate
      • Zoledronic Acid
      • Others
    • Calcitonin 
    • Hormone Therapy 
    • Selective Estrogen Receptor Modulators (SERMs) 
    • Parathyroid Hormone-Related Protein (PTHrP) Analog 
    • Rank Ligand (RANKL) Inhibitor 
  • Global Osteoporosis Treatment Market, By Route of Administration:
    • Oral
    • Injectable
    • Others
  • Global Osteoporosis Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Osteoporosis Treatment Market, By Region:
    • North America
      • By Drug Type
        • Bisphosphonates
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin 
        • Hormone Therapy 
        • Selective Estrogen Receptor Modulators (SERMs) 
        • Parathyroid Hormone-Related Protein (PTHrP) Analog 
        • Rank Ligand (RANKL) Inhibitor 
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Type
        • Bisphosphonates
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin 
        • Hormone Therapy 
        • Selective Estrogen Receptor Modulators (SERMs) 
        • Parathyroid Hormone-Related Protein (PTHrP) Analog 
        • Rank Ligand (RANKL) Inhibitor 
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Type
        • Bisphosphonates
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin 
        • Hormone Therapy 
        • Selective Estrogen Receptor Modulators (SERMs) 
        • Parathyroid Hormone-Related Protein (PTHrP) Analog 
        • Rank Ligand (RANKL) Inhibitor 
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Type
        • Bisphosphonates
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin 
        • Hormone Therapy 
        • Selective Estrogen Receptor Modulators (SERMs) 
        • Parathyroid Hormone-Related Protein (PTHrP) Analog 
        • Rank Ligand (RANKL) Inhibitor 
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Type
        • Bisphosphonates
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin 
        • Hormone Therapy 
        • Selective Estrogen Receptor Modulators (SERMs) 
        • Parathyroid Hormone-Related Protein (PTHrP) Analog 
        • Rank Ligand (RANKL) Inhibitor 
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Type
        • Bisphosphonates
          • Risedronate
          • Ibandronate
          • Zoledronic Acid
          • Others
        • Calcitonin 
        • Hormone Therapy 
        • Selective Estrogen Receptor Modulators (SERMs) 
        • Parathyroid Hormone-Related Protein (PTHrP) Analog 
        • Rank Ligand (RANKL) Inhibitor 
      • By Route of Administration
        • Oral
        • Injectable
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo